Managing dyslipidaemia in patients with chronic kidney disease

Indian Heart J. 2024 Jan 24:S0019-4832(24)00012-9. doi: 10.1016/j.ihj.2024.01.012. Online ahead of print.ABSTRACTPatients with CKD are at increased risk for cardiovascular events. Clinical studies suggest statins reduce all-cause mortality and cardiovascular events in patients with CKD. Lipid lowering therapy with statin with or without ezetemibe is recommended for most of the patients in patients with eGFR <60 mL/min and also in those who have an increased urinary albumin-to-creatinine ratio (≥3 mg/mmol) for at least 3 months. Evidence suggests that it should not be started for hemodialysis patients without evidence of ASCVD. Patients who were already taking statins or statin/ezetimibe combination at the time of dialysis should consider continuing these medications, especially if they have ASCVD. Fibrates should not be used in conjunction with statins in patients with CKD, and ezetimibe monotherapy is also not recommended. The role of PCSK9 inhibitors is evolving suggests that it is effective in lowering LDL cholesterol without affecting the renal outcomes.PMID:38278323 | DOI:10.1016/j.ihj.2024.01.012
Source: Indian Heart J - Category: Cardiology Authors: Source Type: research